- Home
- KZR vs CNC Comparison
KZR vs CNC Comparison
Compare KZR & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- CNC
- Stock Information
- Founded
- KZR 2015
- CNC 1984
- Country
- KZR United States
- CNC United States
- Employees
- KZR N/A
- CNC N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- CNC Medical Specialities
- Sector
- KZR Health Care
- CNC Health Care
- Exchange
- KZR Nasdaq
- CNC Nasdaq
- Market Cap
- KZR 29.7M
- CNC 14.3B
- IPO Year
- KZR 2018
- CNC 2001
- Fundamental
- Price
- KZR $3.75
- CNC $31.79
- Analyst Decision
- KZR Hold
- CNC Hold
- Analyst Count
- KZR 2
- CNC 16
- Target Price
- KZR $9.00
- CNC $38.33
- AVG Volume (30 Days)
- KZR 30.2K
- CNC 14.2M
- Earning Date
- KZR 11-11-2025
- CNC 10-24-2025
- Dividend Yield
- KZR N/A
- CNC N/A
- EPS Growth
- KZR N/A
- CNC N/A
- EPS
- KZR N/A
- CNC 4.07
- Revenue
- KZR N/A
- CNC $159,673,000,000.00
- Revenue This Year
- KZR N/A
- CNC $30.26
- Revenue Next Year
- KZR N/A
- CNC N/A
- P/E Ratio
- KZR N/A
- CNC $7.81
- Revenue Growth
- KZR N/A
- CNC 10.57
- 52 Week Low
- KZR $3.62
- CNC $25.08
- 52 Week High
- KZR $9.18
- CNC $77.29
- Technical
- Relative Strength Index (RSI)
- KZR 36.39
- CNC 56.34
- Support Level
- KZR $3.76
- CNC $28.24
- Resistance Level
- KZR $4.05
- CNC $36.14
- Average True Range (ATR)
- KZR 0.13
- CNC 1.19
- MACD
- KZR 0.00
- CNC 0.54
- Stochastic Oscillator
- KZR 0.00
- CNC 44.94
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.